These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38704439)

  • 61. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
    Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
    Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The incidence and risk factors of recurrent venous thromboembolism during pregnancy.
    Galambosi PJ; Ulander VM; Kaaja RJ
    Thromb Res; 2014 Aug; 134(2):240-5. PubMed ID: 24835671
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
    Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA
    RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
    Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
    Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Factors associated with recurrent venous thromboembolism in patients with malignant disease.
    Lin J; Proctor MC; Varma M; Greenfield LJ; Upchurch GR; Henke PK
    J Vasc Surg; 2003 May; 37(5):976-83. PubMed ID: 12756342
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case-time control study and a nested case-control study based on the French national health insurance (SNDS) cohort.
    Berthe P; Scailteux LM; Lescoat A; Staumont D; Coiffier G; Guéret P; Dupuy A; Oger E; Droitcourt C
    BMJ Open; 2022 Sep; 12(9):e059979. PubMed ID: 36130766
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring.
    Samuel C; Cornman H; Kambala A; Kwatra SG
    Dermatol Ther (Heidelb); 2023 Mar; 13(3):729-749. PubMed ID: 36790724
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
    Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
    JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis.
    Rathore U; Thakare DR; Patro P; Agarwal V; Sharma A; Misra DP
    Clin Rheumatol; 2022 Jan; 41(1):33-44. PubMed ID: 34729652
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of recurrent venous thromboembolism and bleeding in patients with interstitial lung disease: a cohort study.
    Le Mao R; Ropars T; Tromeur C; Barnier A; Hourmant B; Guegan M; Jimenez D; Leroyer C; Lacut K; Couturaud F
    J Thromb Thrombolysis; 2022 Jan; 53(1):67-73. PubMed ID: 34232453
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High Factor VIII Levels and Recurrent Thromboembolism in Patients with and without Inflammatory Bowel Disease: A Retrospective Comparative Study.
    Eagle GE; Schulman S
    TH Open; 2022 Apr; 6(2):e147-e153. PubMed ID: 35707621
    [No Abstract]   [Full Text] [Related]  

  • 74. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
    Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
    BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Venous thromboembolism in pediatric inflammatory bowel disease: an 11-year population-based nested case-control study in Canada.
    Ding Z; Sherlock M; Chan AKC; Zachos M
    Blood Coagul Fibrinolysis; 2022 Dec; 33(8):449-456. PubMed ID: 36409922
    [TBL] [Abstract][Full Text] [Related]  

  • 76. JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies.
    Daniele S; Bunick C
    J Drugs Dermatol; 2022 Dec; 21(12):1298-1303. PubMed ID: 36468956
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.
    Szekanecz Z; Buch MH; Charles-Schoeman C; Galloway J; Karpouzas GA; Kristensen LE; Ytterberg SR; Hamar A; Fleischmann R
    Nat Rev Rheumatol; 2024 Feb; 20(2):101-115. PubMed ID: 38216757
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
    Vallez-Valero L; Gasó-Gago I; Marcos-Fendian Á; Garrido-Alejos G; Riera-Magallón A; Plaza Diaz A; Martinez-Molina C; Mangues-Bafalluy MA; Corominas H
    Clin Rheumatol; 2023 Dec; 42(12):3225-3235. PubMed ID: 37831336
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cardiovascular Risk Management in Patients Treated With Janus Kinase Inhibitors.
    Shah JT; Shah KT; Femia AN; Lo Sicco KI; Merola JF; Weber B; Garshick MS
    J Cardiovasc Pharmacol; 2024 May; 83(5):392-402. PubMed ID: 37566808
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [JAK Inhibitors in Rheumatology].
    Witte T
    Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.